ISSN 2415-3060 (print), ISSN 2522-4972 (online)
  • 19 of 25
УЖМБС 2022, 7(4): 122–130
Humanitarian issues of medicine and problem of teaching at the higher school

Pharmacotherapeutic Features of the Management of Patients with Secondary Arterial Hypertension of Endocrine Genesis

Shuper V. O. , Shuper S. V. 2, Trefanenko I. V. 1, Shumko H. I. 1, Reva T. V. 1

Secondary arterial hypertension is the arterial hypertension, the etiology of which can be established. Secondary arterial hypertension becomes the cause of elevated blood pressure in 5–10% of patients with hypertension. More than 50 diseases and clinical conditions contributing to the development of secondary arterial hypertension have been identified. In most cases, such arterial hypertension is characterized by high blood pressure, an unfavorable prognosis of the disease, and a high frequency of cardiovascular complications. However, in some forms of it, timely diagnosis and adequate treatment allow to achieve normalization of blood pressure and prevent the development of complications. In cases of the secondary arterial hypertension, in addition to antihypertensive therapy, drug treatment or surgical treatment of the underlying disease that caused hypertension is required. Knowledge of modern diagnostics and principles of treatment of these conditions has to improve the quality of care for patients suffering from hypertension. The purpose of the study was to consider the main clinical, pathogenic, diagnostic and pharmacotherapeutic aspects of the secondary arterial hypertension of endocrine genesis. Secondary endocrine arterial hypertensions develop in diabetes mellitus, hyperaldosteronism primary (Kon's syndrome) and pseudoprimary (idiopathic hyperplasia of the adrenal cortex), Itsenko-Cushing syndrome, pheochromocytoma, pheochromoblastoma, paraganglioma, acromegaly, hypothyroidism, hyperthyroidism, hyperparathyroidism, etc. Each of these diseases has a special etiopathogenesis of arterial hypertension, which makes it necessary to carry out special screening and diagnostic tests in order to prescribe reasonable therapy. In the management of patients with secondary endocrine arterial hypertension, there cannot be universal approaches to the appointment of antihypertensive drugs, instead, an individualized approach contributes to effective control of the disease and prevention of possible complications. Conclusion. So, taking into account the high and progressive incidence of arterial hypertension worldwide, the high frequency of life-threatening complications, a large number of risk factors, constant updating of knowledge on the clinical, pathogenic, diagnostic and pharmacotherapeutic aspects of the management of such patients becomes extremely relevant. A significantly large part of secondary arterial hypertension in the structure of this pathology requires special attention of practicing doctors regarding differential diagnosis, especially in the cohort of young patients. Information about features of the pathogenic therapy of the secondary arterial hypertension of endocrine origin is necessary for a wide range of doctors of various specialties for the maximum effective management of such patients

Keywords: secondary arterial hypertension of endocrine genesis, etiopathogenesis, diagnosis, pharmacotherapy

Full text: PDF (Ukr) 262K

  1. Brouwers S, Sudano I, Kokubo Y, Sulaica EM. Arterial hypertension. Lancet. 2021, Jul 17;398(10296):249-261. doi: 10.1016/S0140-6736(21)00221-X
  2. Vedennya khvorogo z arterialnoyu gipertenziyeyu (suchasna praktyka vnutrishnoyi medytsyny z nevidkladnymy stanamy) [Management of a patient with arterial hypertension (modern practice of internal medicine with emergency conditions)]. Metod vkaz dlya studentiv ta likariv-interniv. Uporyad: OYa Babak, MO Vizir, GYu Panchenko. Kharkiv: KhNMU; 2019. 24 s. [Ukrainian]
  3. Rekomendatsiyi z dyferentsiynoyi diagnostyky arterialnykh gipertenziy [Recommendations for the differential diagnosis of arterial hypertension]. Robocha grupa z arterialnoyi gipertenziyi Ukrayinskoyi asotsiatsiyi kardiologiv za uchastyu spetsialistiv-nefrologiv ta endokrynologiv pid kerivnytstvom prof Svishchenka YeP. Kyiv; 2014. 50 s. [Ukrainian]
  4. Rekomendatsiyi Evropeyskogo tovarystva kardiologiv (European Society of Cardiology, ESC) i Yevropeyskogo tovarystva gipertenziyi (European Society of Hypertension, ESH) z likuvannya arterialnoyi gipertenziyi 2018 r. [Recommendations of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH) on the treatment of arterial hypertension in 2018]. Pereklad O Sirenko. Arteryalnaya gypertenzyya. 2018;5(61):58-156. [Ukrainian]
  5. Sertsevo-sudynni zakhvoryuvannya. Klasyfikatsiya, standarty diagnostyky ta likuvannya [Cardiovascular diseases. Classification, standards of diagnosis and treatment]. Za red prof VM Kovalenka, prof MI Lutaya, prof YuM Sirenka. K: Asotsiatsiya kardiologiv Ukrayiny; 2018. 128 s. [Ukrainian]
  6. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39:3021-3104. PMID: 30165516. doi: 10.1093/eurheartj/ehy339
  7. Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2019 Aug. 31. PMID: 31504418. doi: 10.1093/eurheartj/ehz455
  8. Rossi GP, Seccia TM, Pessina AC. Clinical Use of Laboratory Tests for the Identification of Secondary Forms of Arterial Hypertension. Crit Rev Clin Lab Sci. 2007;44(1):1-85. PMID: 17175520. doi: 10.1080/10408360600931831
  9. Thomas RM, Ruel E, Shantavasinkul PC, Corsino L. Endocrine hypertension: An overview on the current etiopathogenesis and management options. World J Hypertens. 2015;5(2):14-27. PMID: 26413481. PMCID: PMC4582789. doi: 10.5494/wjh.v5.i2.14
  10. Jordan J, Kurschat C, Reuter H. Arterial Hypertension. Dtsch Arztebl Int. 2018 Aug 20;115(33-34):557-568. PMID: 30189978. PMCID: PMC6156553. doi: 10.3238/arztebl.2018.0557
  11. Grasso M, Boscaro M, Scaroni C, Ceccato F. Secondary Arterial Hypertension: From Routine Clinical Practice to Evidence in Patients with Adrenal Tumor. High Blood Press Cardiovasc Prev. 2018;25:345–354. PMID: 30415425. doi: 10.1007/s40292-018-0288-6
  12. Vega J, Bisognano JD. The prevalence, incidence, prognosis, and associated conditions of resistant hypertension. Semin Nephrol. 2014 May;34(3):247-56. PMID: 25016397. doi: 10.1016/j.semnephrol.2014.04.002
  13. Greenleaf CE, Griffin LA, Shake JG, Orr WS. Hypertensive crisis secondary to pheochromocytoma. Proc (Bayl Univ Med Cent). 2017 Jul;30(3):314-315. PMID: 28670069. PMCID: PMC5468026. doi: 10.1080/08998280.2017.11929629
  14. Rimoldi SF, Scherrer U, Messerli FH. Secondary arterial hypertension: when, who, and how to screen? Eur Heart J. 2014;35(19):1245–1254. PMID: 24366917. doi: 10.1093/eurheartj/eht534
  15. Baglivo HP, Sánchez RA. Secondary Arterial Hypertension: Improvements in Diagnosis and Management in the Last 10 Years. Amer J Ther. 2011;18(5):403-415. PMID: 21869672. doi: 10.1097/MJT.0b013e3181c0805a
  16. Chiong JR, Aronow WS, Khan IA, Nair CK, Vijayaraghavan K, Dart RA, et al. Secondary hypertension: Current diagnosis and treatment. Int J Cardiol. 2008;124(1):6-21. PMID: 17462751. doi: 10.1016/j.ijcard.2007.01.119
  17. Soliev AU, Rajabova GX, Djumaev KSh. Risk factors for arterial hypertension in elderly patients. Asian J Multidimens Res (AJMR). 2019;8(11):75-80. doi: 10.5958/2278-4853.2019.00308.2